Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003568 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003568: Completed Phase 2 study, sponsored by University of Illinois at Chicago.
NCT00003568 is a Phase 2 study that has completed, run by University of Illinois at Chicago. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003568, a Phase 2 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with interleukin-2 in treating patients with metastatic melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00003568 record still lists
NCT00003568 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which aldesleukin is the first listed.
NCT00003568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003568 about?
NCT00003568 is a clinical study titled "Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with interleukin-2 in treating patients with m...
What is the current status of trial NCT00003568?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-11. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00003568?
The interventions under investigation include: aldesleukin (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003568?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia